Company news
Gentian Diagnostics Asa (OSL:GENT) news
Gentian Diagnostics Asa news releases on 6ix. Latest, Jul 9, 2026: Gentian Diagnostics : Second quarter 2026 report
Press releases & updates
Gentian Diagnostics : Second quarter 2026 report
July 9, 2026
Gentian Diagnostics - Second quarter 2026 report
July 9, 2026
Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
June 24, 2026
Gentian Diagnostics : Join our R&D Team in Gothenburg
May 28, 2026
Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
May 13, 2026
Gentian Diagnostics : Serum calprotectin - marker of systemic inflammation and disease activity
May 12, 2026
GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities
May 6, 2026
Gentian Diagnostics: Invitation to presentation of first quarter results
April 29, 2026
Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
April 20, 2026
Gentian Diagnostics ASA - Registration of share capital increase
April 10, 2026
Gentian Diagnostics : Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis
March 26, 2026
Gentian Diagnostics: Annual report 2025
March 20, 2026
Mandatory notification of trade
February 12, 2026
GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback
February 11, 2026
Gentian Diagnostics: Invitation to presentation of fourth quarter results
February 4, 2026
Gentian Diagnostics invites to NT-proBNP educational webinar
January 28, 2026
Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company
January 7, 2026
Gentian Diagnostics Says Prioritizes Refinement, Causing Minor Ruo Delay
December 18, 2025
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
November 25, 2025
Financial calendar
November 11, 2025
GENT: Strong Q3 growth driven by U.S. sales and Cystatin C, with robust margins and advancing R&D
October 23, 2025
Gentian Diagnostics: Invitation to presentation of third quarter results
October 16, 2025
GENT: Q2 revenue up 14% year-over-year; Cystatin C and U.S. sales drive growth despite margin dip
July 10, 2025
Gentian Diagnostics: Invitation to presentation of second quarter results
July 3, 2025
Disclosure of large shareholding
May 22, 2025
GENT: Record sales, high margins, and robust product growth mark a strong Q1 performance
May 7, 2025
Gentian Diagnostics: Notice of annual general meeting
April 11, 2025
GENT: Gentian achieved record profitability, strong growth, and its first-ever dividend proposal
February 12, 2025
GENT: Strong EBITDA and fCAL turbo growth offset China sales softness; NT-proBNP advances clinically
October 31, 2024
GENT: Q2 2024 saw robust sales, margin gains, and pipeline milestones for Gentian Diagnostics
August 29, 2024